Data Sheet (Cat.No.T0924)



Benzocaine

Chemical Properties


CAS No.: 94-09-7

Formula: C9H11NO2

Molecular Weight: 165.19

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Benzocaine is a surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.			
Targets(IC50)	MRP,Sodium Channel			
In vitro	Benzocaine blocks μ1 wild-type Na+ currents in a dose-dependent manner, with an IC50 of 0.8 mM in HEK293T cells. At 1 mM, Benzocaine inhibits approximately 55% of wild-type Na+ current, about 95% of μ1-N1584A mutant current, and about 80% of μ1-I1575A mutant current. [1] Benzocaine produces a biphasic (protective/inductive) concentration-dependent hemolytic effect on rat erythrocytes, with effective Benzocaine:lipid molar ratios in the membrane for protection (RePROT), onset of hemolysis (ReSAT), and 100% membrane solubilization (ReSOL) at 1.0:1, 1.1:1, and 1.3: 1, respectively. [2] During repetitive pulses, Benzocaine and 4-hydroxybenzoate interact with the open and inactivated channels, but the complex dissociates too rapidly during interpulse to achieve a significant use-dependent Na+ current block. [3] Benzocaine (500 μM) reduces peak and steady-state currents and increases the amplitude of the inactivating component from 21.7% to 30.2% (n=7, P<0.05), resulting in an average block of 30.9% at the end of pulses to +60 mV (n=7). It also significantly accelerates the initial phase of deactivation (τf=27.2±2.6 ms, n=7, P<0.01) without affecting the slow phase of tail current decline. Benzocaine binds with high affinity to an intracellular site producing 'agonist' effects and a low-affinity subsite in the inner mouth producing blocking effects. Benzocaine and extracellular K(+) interact to alter the voltage-dependence of channel opening. [4]			
In vivo	Benzocaine is absorbed rapidly and similarly through both viable and nonviable skin of the hairless guinea pig, the absorption of the two acidic compounds, benzoic acid and PABA, is greater through nonviable skin. [5]			

Solubility Information

Solubility	50: 50 mg/mL (302.68 mM),Sonication is recommended.		
	Ethanol: 31 mg/mL (187.66 mM), Sonication is recommended.		
	(< 1 mg/ml refers to the product slightly soluble or insoluble)		

Page 1 of 2 www.targetmol.com

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	6.0536 mL	30.2682 mL	60.5364 mL
5 mM	1.2107 mL	6.0536 mL	12.1073 mL
10 mM	0.6054 mL	3.0268 mL	6.0536 mL
50 mM	0.1211 mL	0.6054 mL	1.2107 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Wang GK, et al. Pflugers Arch, 1998, 435(2), 293-302. Pinto LM, et al. Biophys Chem, 2000, 87(2-3), 213-223. Quan C, et al. Biophys J, 1996, 70(1), 194-201. Caballero R, et al. Cardiovasc Res, 2002, 56(1), 104-117. Nathan D, et al. Pharm Res, 1990, 7(11), 1147-1151.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com